KRAS mutation in cancer.aThe frequency of KRAS mutations across tumour types, including the mutation frequency of common sites and the subtype with the highest mutation rate in different tumour types. KRAS mutations are characterised by single-base missense mutations, 98% of which are found at codo...
Cancer is the leading cause of death worldwide, and its treatment and outcomes have been dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene, Kirsten rat sarcoma viral oncogene homologue (KRAS) has attracted substantial attention. The understanding of KRAS is ...
参考文献:https://www.mdanderson.org/cancerwise/targeting-the-kras-mutation-for-more-effective-cancer-treatment.h00-159458478.htmlhttps://patientworthy.com/2023/05/17/kras-mutated-colorectal-cancer-tumors-treatment-difficulties/https://www.nejm.org/doi/full/10.1056/NEJMc2208623https://www.nature...
2022年12月13日,Mirati Therapeutics公司研发的KRAZATI(Adagrasib)获FDA批准用于后线治疗携带KRAS G12C突变的局部晚期或转移性非小细胞肺癌患者。 参考文献:https://www.mdanderson.org/cancerwise/targeting-the-kras-mutation-for-more-effective-cancer-treatment.h00-159458478.htmlhttps://patientworthy.com/2023/...
https://www.mdanderson.org/cancerwise/targeting-the-kras-mutation-for-more-effective-cancer-treatment.h00-159458478.html https://patientworthy.com/2023/05/17/kras-mutated-colorectal-cancer-tumors-treatment-difficulties/ https://www.nejm.org/doi/full/10.1056/NEJMc2208623https://www.nature.com/art...
然而,由于KRAS蛋白表面缺乏可供药物结合的口袋,直接针对其突变进行药物靶向治疗一直是个难题。其中,KRAS p.G12C突变体由于其在结构和功能上的特殊性,成为研究的热点和治疗的难点。鉴于此,2023年7月,《Cancers》杂志发表的一篇题为《KRAS p.G12C Mutation in Metastatic Colorectal Cancer: Prognostic Implications...
首页/癌基因/KRAS/ MUTATION KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog)基因是GDP/GTP结合蛋白,比较重要的同家族基因还包括HRAS和NRAS。KRAS与GTP结合呈激活状态,与GDP结合呈关闭状态,KRAS可被生长因子或酪氨酸激酶(如EGFR)短暂活化,活化后的KRAS可以激活下游如控制细胞生成的PI3K-AKT-mTOR信号通路,以及控制细...
https://www.mdanderson.org/cancerwise/targeting-the-kras-mutation-for-more-effective-cancer-treatment.h00-159458478.html [2]美国国家医学图书馆 https://clinicaltrials.gov/ct2/show/NCT03608631 [3]美国国家医学图书馆 https://clinicaltrials.gov/ct2/show/NCT04429542 ...
KRAS G12C 突变作为一种驱动突变,发生在约14%的非小细胞肺癌、3%-4%的结直肠癌和2%的胰腺癌中1。Sotorasib、Adagrasib不仅在KRAS G12C 突变的非小细胞肺癌中显示出令人鼓舞的疗效和安全性,而且在胰腺癌、结直肠癌中也显示出抗肿瘤活性。...
Dong ZY, Zhong WZ, Zhang XC, et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res, 2017, 23(12): 3012-3024. doi: ...